The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in...
-
2018 (v1)PublicationUploaded on: April 14, 2023
-
2022 (v1)Publication
Background Etanercept (ETN) and adalimumab (ADA) are considered equally effective biologicals in the treatment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether ETN and ADA have a differential effect on...
Uploaded on: February 4, 2024 -
2023 (v1)Publication
Objective: The aim of this work was to provide evidence of validity and reliability for 4 parent/child-reported outcome measures included in the Outcome Measures in Rheumatology juvenile idiopathic arthritis core domain set: the evaluation of the child's pain and level of disease activity, the assessment of morning stiffness duration, and an...
Uploaded on: February 14, 2024 -
2020 (v1)Publication
To study growth and puberty in a multi-national longitudinal prospective cohort of juvenile dermatomyositis (JDM).
Uploaded on: April 14, 2023 -
2016 (v1)Publication
To evaluate the demographic, disease activity, disability and health-related quality of life (HRQoL) differences between children with juvenile idiopathic arthritis (JIA) and their healthy peers, and between children with JIA with and without clinical temporomandibular joint (TMJ) involvement and its determinants.
Uploaded on: April 14, 2023